Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-07 4:09 pm Sale |
2024-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
CVI Investments, Inc. | 5,662,500 4.300% |
-2,100,000 (-27.05%) |
Filing History |
| 2024-11-12 1:32 pm Unchanged |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 6,598,296 5.240% |
0 (Unchanged) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
BLACKROCK INC BLK |
9,667,615 7.700% |
0 (Unchanged) |
Filing History |
| 2024-11-04 11:27 am Purchase |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 6,598,296 5.240% |
900,760 (+15.81%) |
Filing History |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
BLACKROCK INC BLK |
9,667,615 7.700% |
6,078,932 (+169.39%) |
Filing History |
| 2023-02-09 11:07 am Sale |
2022-12-30 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 5,697,536 4.500% |
-1,273,314 (-18.27%) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Atossa Therapeutics, Inc. ATOS |
BLACKROCK INC BLK |
3,588,683 2.800% |
-5,950,910 (-62.38%) |
Filing History |
| 2022-02-14 3:16 pm Purchase |
2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
CVI Investments, Inc. | 7,762,500 5.800% |
3,962,500 (+104.28%) |
Filing History |
| 2022-02-09 3:24 pm Purchase |
2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 6,970,850 5.510% |
6,970,850 (New Position) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
BLACKROCK INC BLK |
9,539,593 7.500% |
9,539,593 (New Position) |
Filing History |
| 2022-01-13 10:36 am Sale |
2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
Empery Asset Management, LP | 1,312,500 1.030% |
-3,448,000 (-72.43%) |
Filing History |
| 2021-01-15 4:09 pm Purchase |
2020-01-06 | 13G | Atossa Therapeutics, Inc. ATOS |
Mitchell P. Kopin | 3,749,923 4.990% |
1,499,923 (+66.66%) |
Filing History |
| 2021-01-15 11:42 am Purchase |
2021-01-06 | 13G | Atossa Therapeutics, Inc. ATOS |
CVI Investments, Inc. | 3,800,000 5.300% |
1,495,711 (+64.91%) |
Filing History |
| 2021-01-15 11:41 am Purchase |
2020-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
CVI Investments, Inc. | 2,304,289 4.900% |
179,289 (+8.44%) |
Filing History |
| 2021-01-14 09:00 am Purchase |
2021-01-06 | 13G | Atossa Therapeutics, Inc. ATOS |
Empery Asset Management, LP | 4,760,500 5.320% |
4,760,500 (New Position) |
Filing History |
| 2020-12-28 06:14 am Purchase |
2020-12-17 | 13G | Atossa Therapeutics, Inc. ATOS |
Mitchell P. Kopin | 2,250,000 4.900% |
2,150,032 (+2150.72%) |
Filing History |
| 2020-12-18 12:01 pm Purchase |
2020-12-09 | 13G | Atossa Therapeutics, Inc. ATOS |
CVI Investments, Inc. | 2,125,000 8.500% |
2,125,000 (New Position) |
Filing History |